(Q53372767)

13 May 2018

editorial

0 references

title

Emerging amyloid disease-modifying drugs for Alzheimer's disease. (English)

1 reference

13 May 2018

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26817686%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Daniela Galimberti

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26817686%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

1

Daniela Galimberti

1 reference

13 May 2018

language of work or name

English

0 references

publication date

15 February 2016

1 reference

13 May 2018

Expert Opinion on Emerging Drugs

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26817686%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26817686%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26817686%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

page(s)

5-7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26817686%20AND%20SRC:MED&resulttype=core&format=json

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

11 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2016.1146678

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2016.1146678

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2016.1146678

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2016.1146678

Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2016.1146678

Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2016.1146678

A noninflammatory immune response in aged DNA Aβ42-immunized mice supports its safety for possible use as immunotherapy in AD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2016.1146678

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2016.1146678

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2016.1146678

Solanezumab for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2016.1146678

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2016.1146678

Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2016.1146678

Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2016.1146678

BRICHOS binds to a designed amyloid-forming β-protein and reduces proteasomal inhibition and aggresome formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2016.1146678

Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2016.1146678

10.1517/14728214.2016.1146678

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26817686%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

1 reference